Pooled evidence finds no statistically significant increase in depression, anxiety or suicidal thoughts among people taking semaglutide compared with placebo or other treatments. The authors stress this is an absence of detected risk in noisy data, not definitive proof of safety.
What it shows: Reassuring rather than final: the pooled sources, from proper trials to voluntary side-effect reports, disagreed with each other sharply and some carried real risk of bias. That messiness means a modest effect in either direction cannot be ruled out.Meta-analysis · Clin Obes